Cambridge Researchers Test AI-Designed Coronavirus Vaccine in Early Human Trial
The vaccine was safe in 39 healthy volunteers and triggered immune responses to SARS-CoV-2, SARS and related bat viruses, researchers said.
- Researchers at the University of Cambridge and DIOSynVax developed an AI-designed 'super-antigen' vaccine offering protection against entire families of viruses rather than just specific strains.
- Artificial intelligence analyzed genetic codes from various coronaviruses to identify essential, unchanging elements across virus families, creating a 'fundamentally new' approach that future-proofs against mutations.
- A phase I trial in Cambridge and Southampton involving 49 healthy volunteers aged 18 to 50 confirmed the vaccine is safe and triggered immune responses against SARS-CoV-2, SARS, and related bat viruses.
- More than 200 individuals will be recruited for a forthcoming phase II study, with Professor Jonathan Heeney calling the technology a 'game changer' for vaccine development.
- Scientists are now exploring applications for other virus families, including Ebola and bird flu, aiming to prevent pandemics before they start and potentially save millions of lives.
72 Articles
72 Articles
Computer-designed universal vaccine shows early human trial success
A Cambridge-led team has developed an early-stage vaccine platform that uses computational design to generate broad immune protection against entire virus families, with the aim of reducing the need to repeatedly update vaccines as viruses mutate. The approach, developed by researchers at the University of Cambridge and spin-out DIOSynVax (DVX) Ltd, has now reached a key milestone after its first human clinical trial showed safety and immune res…
Researchers at the University of Cambridge in the United Kingdom have discovered a new way to develop vaccines with the help of artificial intelligence. This should make it possible to produce vaccines that offer immediate protection against an entire family of viruses.
Researchers Push AI DESIGNED ‘Super Vaccine’
Cambridge scientists are hailing an AI-crafted “super-antigen” as a breakthrough that could ‘get ahead of pandemics’, blanket-protect against every COVID variant, and spare the world future lockdowns while saving millions of lives. Yet the same public that lived through the last round of experimental shots is not buying the hype. Responses to the announcements have been blunt, laced with references to documented harms, AI’s well-known limitation…
Artificial intelligence managed to surprise again.
A team of British researchers, led by scientists at the universities of Cambridge and Southampton in the United Kingdom, has developed the first vaccine designed entirely by AI to be tested in humans. “Viruses such as influenza, coronaviruses and the Ebola group are constantly evolving, and when vaccines become available, they may not be compatible with each other - the current reactive vaccine system is struggling to keep up,” said Professor Sa…
Coverage Details
Bias Distribution
- 45% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
